Retatrutide (Research Overview)
(Research Overview)
Mechanism of Action
Retatrutide is a synthetic peptide designed to simultaneously activate three incretin-related receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple agonism distinguishes it from earlier dual-agonist compounds studied in the same metabolic research space.
GLP-1R activation is associated with glucose-dependent insulin secretion and appetite-regulating signaling pathways. GIPR co-agonism has been studied for its potential to modulate GLP-1R-mediated effects, including gastrointestinal tolerability. The addition of GCGR agonism introduces a third pathway that researchers have investigated for its role in energy expenditure and hepatic glucose output.
Research Areas
Published clinical research has examined Retatrutide primarily in the context of metabolic dysfunction. Phase 2 trial data published in peer-reviewed literature reported substantial reductions in body weight measures among study participants over 24-week and 48-week observation periods. Researchers have also examined its effects on glycemic markers, lipid profiles, and hepatic fat content in controlled study settings.
The glucagon receptor component has drawn particular research interest because of its theoretical contribution to energy expenditure — a mechanism not present in GLP-1/GIP dual agonists. Preclinical and early clinical data have been used to model whether this additional receptor engagement produces additive or synergistic effects on metabolic outcomes.
Secondary research areas include cardiovascular risk markers, non-alcoholic fatty liver disease (NAFLD) endpoints, and the relationship between incretin receptor co-agonism and lean mass preservation during caloric restriction studies.
Specification summary
Retatrutide
Our Retatrutide research compound is a triple agonist peptide. Stated purity ≥99%. For laboratory research use only.
Related materials
References
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315 · DOI
- Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID 37385280 · DOI
- Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID 38858523 · DOI
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID 35985340 · DOI
- Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, et al. The power of three: Retatrutide's role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;985:177095. PMID 39515565 · DOI
- Winther JB, Holst JJ. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity. Diabetes Obes Metab. 2024;26(9):3501-3512. PMID 38853300 · DOI
Cited literature is provided for scientific context only and does not describe or endorse any use of these products.
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.